Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$68.54 USD
+4.00 (6.20%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $68.53 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.54 USD
+4.00 (6.20%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $68.53 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
What's in Store for Intuitive Surgical (ISRG) in Q3 Earnings?
by Zacks Equity Research
Better-than-expected performance at Instruments & Accessories segment and da Vinci procedure growth are likely to aided Intuitive Surgical (ISRG) in Q3 earnings.
Edwards Lifesciences Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Edwards Lifesciences (EW) has been consistently delivering impressive results.
Will Edwards Lifesciences (EW) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT
by Zacks Equity Research
Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
by Zacks Equity Research
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
What Makes Edwards Lifesciences (EW) a New Buy Stock
by Zacks Equity Research
Edwards Lifesciences (EW) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stock Investors: Do You Need a Late Cycle Plan?
by Tracey Ryniec
The financial media keeps talking about the economy being in the late cycle but that doesn't mean you can't be buying stocks.
Edwards Lifesciences Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Edwards Lifesciences (EW) gains from recent impressive developments.
Here's Why You Should Invest in Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edwards Lifesciences' (EW) performance.
Edwards Lifesciences Sapien 3 System Recall Classified Class I
by Zacks Equity Research
Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.
Why Is Edwards Lifesciences (EW) Up 3.2% Since Last Earnings Report?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences' (EW) SAPIEN 3 TAVR Receives FDA Nod
by Zacks Equity Research
Edwards Lifesciences (EW) plans a commercial introduction of SAPIEN 3 Ultra in Europe.
HMS Holdings (HMSY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
HMS Holdings (HMSY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here is Why Growth Investors Should Buy Edwards Lifesciences (EW) Now
by Zacks Equity Research
Edwards Lifesciences (EW) could produce exceptional returns because of its solid growth attributes.
Edwards Lifesciences Corporation (EW) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Edwards Lifesciences Corporation (EW).
Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
by Zacks Equity Research
Edwards Lifesciences (EW) Q2 results benefit from higher revenues, strong segmental performance and gross margin expansion.
Edwards Lifesciences (EW) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.76% and 4.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Edwards Lifesciences' (EW) Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is likely to deliver a solid second quarter on robust segmental performance.
Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
This $6 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies
Edwards Lifesciences Recalls Heart Device on Balloon Rupture
by Zacks Equity Research
Shares of Edwards Lifesciences (EW) decline post product recall news.
CMS' Final Verdict on TAVR: A Boon or Bane for MedTech?
by Urmimala Biswas
While the industry bigwigs are keen to welcome the new CMS ruling, companies like Heart Valve Voice US are not lagging to pen their resistance against a revised policy.
HOLX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
DexCom and Companion Medical Collaboration to Support CGM
by Zacks Equity Research
The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.
Why Is Edwards Lifesciences (EW) Down 2.9% Since Last Earnings Report?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.